US beauty products powerhouse The Estée Lauder Companies (ELC) yesterday (29 April) announced a minority investment in 111SKIN, a UK luxury clinical skincare brand founded in 2012 by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides.
111SKIN was developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is NAC Y2, described by The Estée Lauder Companies as a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion.
Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from US$50 to US$1,000.
“Skincare is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” said The Estée Lauder Companies President and Chief Executive Officer Stéphane de La Faverie.
“111SKIN exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skincare inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy.
“This investment, grounded in consumer-centricity and transformative innovation, reflects our Beauty Reimagined vision and underscores the significant opportunity we see to support the brand’s continued growth – expanding its global reach while preserving the distinctive approach that has made it so relevant with today’s consumers.”
The Estée Lauder Companies noted that 111SKIN is a luxury clinical skincare brand, operating in a fast-growing segment where medical expertise and powerful high-performance formulations are increasingly shaping consumer demand.
The brand distributes through luxury retail, e-commerce and high-end spa channels – including Harrods, Bluemercury, Nordstrom, Mandarin Oriental and Aman – and has a robust direct-to-consumer business representing approximately 20% of sales, reflecting strong digital engagement with prestige consumers.
The brand has a diversified global footprint, with North America representing approximately 40% of 2025 sales, and an established presence across China, the UK, continental Europe and Asia Pacific.
“We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111SKIN,” said 111SKIN Co-Founders Dr. Yannis Alexandrides and Eva Alexandrides.
“We look forward to building on our momentum and driving future growth together,” added 111SKIN CEO Vanessa Goddevrind.
Dr. Alexandrides will remain actively involved in the brand and will continue to lead 111SKIN alongside its experienced management team.
The Estée Lauder Companies said the investment aligns with the group’s continued focus on science-driven innovation, as 111SKIN’s advanced NAC Y2 technology and commitment to clinical-led product development reflect consumers’ growing preference for high-performance and preventative skincare.
